1. HDAC6: A unique HDAC family member as a cancer target
   Sumeet Kaur et al, 2022, Cellular Oncology CrossRef
2. Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma
   Huimin Lei et al, 2022, Frontiers in Oncology CrossRef
3. TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer
   Akiko Arimura et al, 2024, Cancers CrossRef
4. HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis
   Lihong Yang et al, 2024, BMC Cancer CrossRef
5. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe
   Rahman Ud Din et al, 2023, International Journal of Molecular Sciences CrossRef
6. Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets
   Mengchen Xu et al, 2024, Journal of Translational Medicine CrossRef
7. Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma
   Husvinee Sundaramurthi et al, 2022, International Journal of Molecular Sciences CrossRef
8. Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
   Hyein Jo et al, 2022, International Journal of Molecular Sciences CrossRef
9. Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases
   Jianglei Li et al, 2022, Frontiers in Pharmacology CrossRef
10. Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma
    Tsutomu Anraku et al, 2024, Journal of Personalized Medicine CrossRef